BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Calderasib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Calderasib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06345729-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Calderasib: Phase 3 readout est. (NCT06345729)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants W
 ith KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Ce
 ll Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004
 /KANDLELIT-004)\nEstimated primary completion: 24 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06345729
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05853367-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20280624
DTEND;VALUE=DATE:20280625
SUMMARY:Calderasib: Phase 1 readout est. (NCT05853367)
DESCRIPTION:Calderasib\, phase 1.\nStudy: Study of MK-0472 in Participants 
 With Advanced/Metastatic Solid Tumors (MK-0472-001)\nEstimated primary com
 pletion: 24 June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/calderasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05853367
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06997497-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20290328
DTEND;VALUE=DATE:20290329
SUMMARY:Calderasib: Phase 3 readout est. (NCT06997497)
DESCRIPTION:Calderasib\, phase 3.\nStudy: A Clinical Study of Calderasib (M
 K-1084) With Targeted Therapy and Chemotherapy in People With Colorectal C
 ancer (MK-1084-012/KANDLELIT-012)\nEstimated primary completion: 28 March 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/calderasib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06997497
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Calderasib: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Calderasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Ca
 ncer (MK-3475-01F)\nEstimated primary completion: 17 August 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07286149
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252739-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Calderasib: Phase 2 readout est. (NCT07252739)
DESCRIPTION:Calderasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: KEYM
 AKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participan
 ts With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral 
 Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)\nEstima
 ted primary completion: 15 November 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/calderasib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07252739
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190248-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20291207
DTEND;VALUE=DATE:20291208
SUMMARY:Calderasib: Phase 3 readout est. (NCT07190248)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Study of Calderasib (MK-1084) and Other Treatments for Participants
  With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)\nEstimated pr
 imary completion: 7 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/calderasib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07190248
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05067283-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20300225
DTEND;VALUE=DATE:20300226
SUMMARY:Calderasib: Phase 1 readout est. (NCT05067283)
DESCRIPTION:Calderasib\, phase 1.\nStudy: A Study of Calderasib (MK-1084) i
 n KRAS Mutant Advanced Solid Tumors (MK-1084-001)\nEstimated primary compl
 etion: 25 February 2030. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/calderasib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05067283
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209111-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20320409
DTEND;VALUE=DATE:20320410
SUMMARY:Calderasib: Phase 2 readout est. (NCT07209111)
DESCRIPTION:Calderasib\, phase 2.\nStudy: A Clinical Study of Calderasib (M
 K-1084) in People With Advanced Solid Tumors (MK-1084-014)\nEstimated prim
 ary completion: 9 April 2032. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/calderasib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07209111
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554339-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20321215
DTEND;VALUE=DATE:20321216
SUMMARY:Calderasib: Phase 3 readout est. (NCT07554339)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Sma
 ll Cell Lung Cancer (MK-1084-015/KANDLELIT-015)\nEstimated primary complet
 ion: 15 December 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/calderasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07554339
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431827-1988@assetmemo.bio
DTSTAMP:20261121T005822Z
DTSTART;VALUE=DATE:20391026
DTEND;VALUE=DATE:20391027
SUMMARY:Calderasib: Phase 3 readout est. (NCT07431827)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: MK-3
 475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS
  G12Cm NSCLC (MK-1084-013)\nEstimated primary completion: 26 October 2039.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07431827
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
